GEHC
A pricey side quest
GE Healthcare Technologies is apparently hunting for a new growth lever, and it comes with a hefty price tag: about $1 billion for Sofie Biosciences. Sofie makes the radioactive chemicals used in cancer scans, which would beef up GEHC’s pharmaceutical diagnostics division — basically the part of the business that helps scanners actually find things.
Why this matters
This isn’t just random empire-building. GE Healthcare has been the laggard of the old General Electric breakup, with the stock down more than 32% from its all-time high while GE Aerospace and GE Vernova have gotten most of the glow-up. So when a company starts shopping in the billion-dollar aisle, it usually means management is trying to fix a story that isn’t exciting enough on its own.
The growth puzzle
The latest quarter showed the problem pretty clearly:
- revenue was up just 3.5% to $5.3 billion
- free cash flow came in at $68 million
- patient care solutions revenue fell 13%
Meanwhile, the pharmaceutical diagnostics business brought in $843 million, which is exactly why Sofie is interesting — it would deepen a segment that’s already relevant instead of forcing GEHC to invent a whole new playbook.
Big picture
GE Healthcare is trying to turn a sleepy post-spin-off chart into something with more narrative juice. A deal like this won’t magically fix the stock, but it could make the company look a lot more like a strategic buyer and a lot less like the forgotten sibling in the GE family reunion.